Multimodal treatment of resectable pancreatic ductal adenocarcinoma

Nicola Silvestris; Oronzo Brunetti; Enrico Vasile; Francesco Cellini; Ivana Cataldo; Valeria Pusceddu; Monica Cattaneo; Stefano Partelli; Mario Scartozzi; Giuseppe Aprile; Andrea Casadei Gardini; Alessio Giuseppe Morganti; Vincenzo Valentini; Aldo Scarpa; Massimo Falconi; Angela Calabrese; Vito Lorusso; Michele Reni; Stefano Cascinu

doi:10.1016/j.critrevonc.2017.01.015

Multimodal treatment of resectable pancreatic ductal adenocarcinoma

Nicola Silvestris, Oronzo Brunetti, Enrico Vasile, Francesco Cellini, Ivana Cataldo, Valeria Pusceddu, Monica Cattaneo, Stefano Partelli, Mario Scartozzi, Giuseppe Aprile, Andrea Casadei Gardini, Alessio Giuseppe Morganti, Vincenzo Valentini, Aldo Scarpa, Massimo Falconi, Angela Calabrese, Vito Lorusso, Michele Reni, Stefano Cascinu

Research output: Contribution to journal › Review article › peer-review

Abstract

After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.

Original language	English
Pages (from-to)	152-165
Number of pages	14
Journal	Critical Reviews in Oncology/Hematology
Volume	111
DOIs	https://doi.org/10.1016/j.critrevonc.2017.01.015
Publication status	Published - Mar 1 2017

Keywords

Adjuvant
Chemotherapy
Pancreatic ductal adenocarcinoma
Radiotherapy
Target therapy

ASJC Scopus subject areas

Hematology
Oncology
Geriatrics and Gerontology

Access to Document

10.1016/j.critrevonc.2017.01.015

Fingerprint Dive into the research topics of 'Multimodal treatment of resectable pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this

Silvestris, N., Brunetti, O., Vasile, E., Cellini, F., Cataldo, I., Pusceddu, V., Cattaneo, M., Partelli, S., Scartozzi, M., Aprile, G., Casadei Gardini, A., Morganti, A. G., Valentini, V., Scarpa, A., Falconi, M., Calabrese, A., Lorusso, V., Reni, M., & Cascinu, S. (2017). Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 111, 152-165. https://doi.org/10.1016/j.critrevonc.2017.01.015

Multimodal treatment of resectable pancreatic ductal adenocarcinoma. / Silvestris, Nicola ; Brunetti, Oronzo; Vasile, Enrico; Cellini, Francesco; Cataldo, Ivana; Pusceddu, Valeria; Cattaneo, Monica; Partelli, Stefano; Scartozzi, Mario; Aprile, Giuseppe; Casadei Gardini, Andrea; Morganti, Alessio Giuseppe; Valentini, Vincenzo; Scarpa, Aldo; Falconi, Massimo; Calabrese, Angela; Lorusso, Vito ; Reni, Michele; Cascinu, Stefano.

In: Critical Reviews in Oncology/Hematology, Vol. 111, 01.03.2017, p. 152-165.

Research output: Contribution to journal › Review article › peer-review

Silvestris, N , Brunetti, O, Vasile, E, Cellini, F, Cataldo, I, Pusceddu, V, Cattaneo, M, Partelli, S, Scartozzi, M, Aprile, G, Casadei Gardini, A, Morganti, AG, Valentini, V, Scarpa, A, Falconi, M, Calabrese, A, Lorusso, V , Reni, M & Cascinu, S 2017, 'Multimodal treatment of resectable pancreatic ductal adenocarcinoma', Critical Reviews in Oncology/Hematology, vol. 111, pp. 152-165. https://doi.org/10.1016/j.critrevonc.2017.01.015

Silvestris, Nicola ; Brunetti, Oronzo ; Vasile, Enrico ; Cellini, Francesco ; Cataldo, Ivana ; Pusceddu, Valeria ; Cattaneo, Monica ; Partelli, Stefano ; Scartozzi, Mario ; Aprile, Giuseppe ; Casadei Gardini, Andrea ; Morganti, Alessio Giuseppe ; Valentini, Vincenzo ; Scarpa, Aldo ; Falconi, Massimo ; Calabrese, Angela ; Lorusso, Vito ; Reni, Michele ; Cascinu, Stefano. / Multimodal treatment of resectable pancreatic ductal adenocarcinoma. In: Critical Reviews in Oncology/Hematology. 2017 ; Vol. 111. pp. 152-165.

@article{6dba156a124d46f198e8c3fa2fdb9a55,

title = "Multimodal treatment of resectable pancreatic ductal adenocarcinoma",

abstract = "After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.",

keywords = "Adjuvant, Chemotherapy, Pancreatic ductal adenocarcinoma, Radiotherapy, Target therapy",

author = "Nicola Silvestris and Oronzo Brunetti and Enrico Vasile and Francesco Cellini and Ivana Cataldo and Valeria Pusceddu and Monica Cattaneo and Stefano Partelli and Mario Scartozzi and Giuseppe Aprile and {Casadei Gardini}, Andrea and Morganti, {Alessio Giuseppe} and Vincenzo Valentini and Aldo Scarpa and Massimo Falconi and Angela Calabrese and Vito Lorusso and Michele Reni and Stefano Cascinu",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.critrevonc.2017.01.015",

language = "English",

volume = "111",

pages = "152--165",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Multimodal treatment of resectable pancreatic ductal adenocarcinoma

AU - Silvestris, Nicola

AU - Brunetti, Oronzo

AU - Vasile, Enrico

AU - Cellini, Francesco

AU - Cataldo, Ivana

AU - Pusceddu, Valeria

AU - Cattaneo, Monica

AU - Partelli, Stefano

AU - Scartozzi, Mario

AU - Aprile, Giuseppe

AU - Casadei Gardini, Andrea

AU - Morganti, Alessio Giuseppe

AU - Valentini, Vincenzo

AU - Scarpa, Aldo

AU - Falconi, Massimo

AU - Calabrese, Angela

AU - Lorusso, Vito

AU - Reni, Michele

AU - Cascinu, Stefano

PY - 2017/3/1

Y1 - 2017/3/1

N2 - After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.

AB - After a timing preoperative staging, treatment of resectable pancreatic adenocarcinoma (PDAC) includes surgery and adjuvant therapies, the former representing the initial therapeutic option and the latter aiming to reduce the incidence of both distant metastases (chemotherapy) and locoregional failures (chemoradiotherapy). Herein, we provide a critical overview on the role of multimodal treatment in PDAC and on new opportunities related to current more active poli-chemotherapy regimens, targeted therapies, and the more recent immunotherapy approaches. Moreover, an analysis of pathological markers and clinical features able to help clinicians in the selection of the best therapeutic strategy will be discussed. Lastly, the role of neoadjuvant treatment of initially resectable disease will be considered mostly in patients whose malignancy shows morphological but not clinical or biological criteria of resectability. Depending on the results of these investigational studies, today a multidisciplinary approach can offer the best address therapy for these patients.

KW - Adjuvant

KW - Chemotherapy

KW - Pancreatic ductal adenocarcinoma

KW - Radiotherapy

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85014128206&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014128206&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2017.01.015

DO - 10.1016/j.critrevonc.2017.01.015

M3 - Review article

C2 - 28259290

AN - SCOPUS:85014128206

VL - 111

SP - 152

EP - 165

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -